Library

Cross-border genetic testing of rare diseases

Methods for carrying out genetic testing are developing at an unprecedented and unforeseen rate. Simultaneously, the overall number of genes linked to rare diseases (RD) is increasing. This means that it is now possible to provide an etiological diagnosis for several thousand RD(or ‘Mendelian’ diseases). Although accurate diagnosis enables specific treatment for only a minority

Cross-border genetic testing of rare diseases Read More »

Novel food

New rules on novel food aim to improve conditions, so that businesses can more easily bring new and innovative food to the EU market, while still maintaining a high level of food safety for European consumers. It will offer European consumers the benefit of a broader choice of food and a more favourable environment for

Novel food Read More »

Multi-morbidity

There are already an estimated 50 million people in the EU suffering from two or more long-term conditions and by 2020, when a quarter of Europeans will be over 60 years of age, multi-morbidity is likely to be the norm rather than the exception. Multi-morbidity has significant implications for the economy, labour market, social security

Multi-morbidity Read More »

Harmonising pharmaceuticals for human use

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has been reconfigured to transform it into a truly global initiative with robust and transparent governance mechanisms. The ICH will promote public health through international harmonisation of technical requirements for the authorisation and regulatory oversight of medicinal products. This will help

Harmonising pharmaceuticals for human use Read More »

Scroll to Top